The "gray market" raises concerns about cost, safety, and ethics.

Journal of the National Cancer Institute

Volumn 104, Issue 3, 2012, Pages 168-170

  Rosenthal, Eric T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERTIZING; DRUG COST; DRUG LEGISLATION; ECONOMICS; ETHICS; FOOD AND DRUG ADMINISTRATION; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; METHODOLOGY; NOTE; PATIENT SAFETY; POLITICS; UNITED STATES;

ADVERTISING AS TOPIC; ANTINEOPLASTIC AGENTS; DRUG COSTS; ETHICS, MEDICAL; HUMANS; LEGISLATION, DRUG; PATIENT SAFETY; POLITICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84858791719     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs024     Document Type: Note

References (0)